Benzinga | Sep 18, 2020 09:05AM EDT

Natera Reports Will Present New Data On Personalized Molecular Residual Disease Test, Signatera, At European Society For Medical Oncology Sept. 19-21

Natera, Inc. (NASDAQ:NTRA), a pioneer and global leader in cell-free DNA testing, today announced it will present new data on its personalized molecular residual disease (MRD) test, Signatera, at the 2020 European Society for Medical Oncology (ESMO) virtual meeting taking place September 19-21, 2020.



Natera will present four abstracts -- one oral and three poster presentations -- which highlight applications for detecting MRD levels and tracking tumor clonal evolution in CRC and in esophageal adenocarcinoma.

"When CRC patients present with multiple lesions, recurrence monitoring may be complicated by spatial heterogeneity between the primary tumor and the metastases," said Andr?s Cervantes, M.D., Ph.D., President-Elect of ESMO and co-author of the tumor evolution study. "Our study leverages a tumor-informed ctDNA technology that can evaluate and account for this heterogeneity."

"We're delighted to share new data at this year's ESMO meeting, which shows the broad potential of our tumor-informed approach to MRD assessment," said Alexey Aleshin, M.D., M.B.A., Senior Medical Director of Oncology at Natera. "These studies demonstrate that Signatera provides clinically actionable information that can improve the management of patients with multiple different solid cancers."

Details about the abstracts are as follows:

Abstract #405MO | Mini Oral Presentation

Presenter: Fotios Loupakis, M.D., Ph.D.

Personalized circulating tumor DNA assay for the detection of minimal residual disease in CRC patients undergoing resections of metastases.

This study evaluated the prognostic value of MRD testing after surgical resection of metastases. MRD positivity correlated with inferior progression-free survival and was the most significant biomarker for prognosis in patients with oligometastatic CRC.

Abstract #420P | Poster Presentation

Presenter: Tenna V. Henriksen, M.S.

MRD detection and tracking tumor evolution using ctDNA in stage I-III colorectal cancer patients

A prospective, multicenter cohort study that analyzed the genetic heterogeneity between primary tumor, metastases, and synchronous tumors in patients with stage I-III CRC using Signatera. While primary and metastatic tumors showed at least 50 percent phylogenetic similarity, synchronous CRC tumors were observed to be genetically unrelated and required individual Signatera assays to be designed for reliable ctDNA detection.

Abstract #1491P | Poster Presentation

Presenter: Emma Ococks, M.S.

Bespoke circulating tumor DNA assay for the detection of minimal residual disease in esophageal adenocarcinoma patients

A pilot study that evaluated the ability of tumor-informed ctDNA testing to assess MRD status in patients with esophageal adenocarcinoma, a low-shedding tumor type. Postoperative assessment of MRD detected clinical relapse with a median lead time of 335 days and with 100 percent sensitivity.

Abstract #520TiP | Poster Presentation

Presenter: Pashtoon Kasi, M.D., M.S.

A multicenter study to evaluate the impact of circulating tumor DNA guided therapy (BESPOKE) in patients with Stage II and III colorectal cancer

A trial-in-progress poster presentation, describing the first real-world, prospective, multicenter study (BESPOKE) utilizing a tumor-informed ctDNA test to assess MRD status in 1000 patients with stage II and III CRC over the course of two years. The primary endpoint of this study is to examine the impact of Signatera on adjuvant treatment decisions and to determine the rates of CRC recurrence while asymptomatic.